Celgene Quick Ratio (CELG) starting from the third quarter 2019 to third quarter 2018, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Celgene Corp  (NASDAQ: CELG)

Celgene's Quick Ratio

CELG's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2019, Quick Ratio fell to 2.17 below Celgene Corp average.

Within Major Pharmaceutical Preparations industry 319 other companies have achieved higher Quick Ratio than Celgene in third quarter 2019. While Quick Ratio total ranking has improved so far during the Q3 2019 to 1138, from total ranking in the second quarter 2019 at 1157.

Explain Quick Ratio?
How much Cash & cash equivalents CELG´s has?
What are CELG´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CELG Quick Ratio (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1		 (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3
Y / Y Current Liabilities Change 36 % -18.15 % 26.97 % -64.18 % 75.46 %
Y / Y Cash & cash equivalent Change 152.39 % 161.48 % 50.41 % -45.8 % -63.33 %
Quick Ratio MRQ 2.17 2.36 1.78 5.18 1.17
CELG's Total Ranking # 1138 # 1157 # 1150 # 1641 # 1590
Seq. Current Liabilities Change 35.93 % -6.83 % 269.63 % -70.95 % -18.19 %
Seq. Cash & cash equivalent Change 24.95 % 23.95 % 26.7 % 28.62 % 29.45 %



Quick Ratio third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 320
Healthcare Sector # 523
Overall Market # 1138


Quick Ratio Statistics
High Average Low
15.78 3.83 0.74
(March 31, 2007)   (Jun 30 2018)




Financial Statements
Celgene's Current Liabilities $ 5,009 Millions Visit CELG's Balance sheet
Celgene's Cash & cash equivalent $ 10,883 Millions Visit CELG's Balance sheet
Source of CELG's Sales Visit CELG's Sales by Geography


Cumulative Celgene's Quick Ratio

CELG's Quick Ratio for the trailling 12 Months

CELG Quick Ratio

 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months
Y / Y Current Liabilities TTM Growth -3.98 % -2.44 % 15.46 % 12.92 % 26.43 %
Y / Y Cash & cash equivalent TTM Growth 42.66 % -14.67 % -45.07 % -56.43 % -44.07 %
Quick Ratio TTM 2.34 2.07 1.53 1.44 1.58
Total Ranking TTM # 4575 # 4481 # 914 # 1320 # 4595
Seq. Current Liabilities TTM Growth 10.7 % -6.18 % 6.79 % -13.42 % 12.47 %
Seq. Cash & cash equivalent TTM Growth 25.67 % 26.61 % 13.19 % -20.78 % -24.83 %

Quick ratio ranking by company, industry and sector >> Back to CELG Financial Strength Comparisons >> Go to Compare CELG Quick Ratio to its Competitors

On the trailing twelve months basis CELG Cash & cash equivalent more than doubled by 152.39 % in Q3 2019 year on year, faster than Current Liabilities, this led to increase in in Celgene's Quick Ratio to 2.34, Quick Ratio remained below CELG average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 459 other companies have achieved higher Quick Ratio than Celgene. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2019 from 4481 to 4575.

Explain Quick Ratio?
How much Cash & cash equivalents CELG´s has?
What are CELG´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 460
Healthcare Sector # 894
Within the Market # 4575


trailing twelve months Quick Ratio Statistics
High Average Low
7.91 3.67 1.11
(March 31, 2007)   (Dec 31 2018)




Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2019 MRQ Cash & cash equivalentSep 30 2019 MRQ Current Liabilities
Ardelyx inc   5.86 $ 103.543  Millions$ 17.679  Millions
Kala Bio inc   5.84 $ 97.556  Millions$ 16.717  Millions
Gw Pharmaceuticals Plc  5.82 $ 554.682  Millions$ 95.265  Millions
Travere Therapeutics Inc   5.80 $ 407.023  Millions$ 70.117  Millions
Constellation Pharmaceuticals Inc  5.79 $ 89.066  Millions$ 15.372  Millions
Spyre Therapeutics Inc   5.76 $ 88.700  Millions$ 15.396  Millions
Xeris Biopharma Holdings Inc   5.76 $ 102.471  Millions$ 17.792  Millions
Adamas Pharmaceuticals Inc  5.70 $ 150.240  Millions$ 26.358  Millions
Reata Pharmaceuticals Inc   5.57 $ 240.149  Millions$ 43.141  Millions
Amicus Therapeutics inc   5.52 $ 514.194  Millions$ 93.081  Millions
Portola Pharmaceuticals inc   5.49 $ 480.008  Millions$ 87.491  Millions
Proqr Therapeutics N v   5.44 $ 81.561  Millions$ 14.983  Millions
Tempest Therapeutics Inc   5.44 $ 47.151  Millions$ 8.664  Millions
Verastem Inc   5.32 $ 160.228  Millions$ 30.131  Millions
Nabriva Therapeutics Plc  5.26 $ 78.276  Millions$ 14.884  Millions
Blueprint Medicines Corporation  5.24 $ 493.442  Millions$ 94.142  Millions
Spectrum Pharmaceuticals Inc   5.18 $ 247.762  Millions$ 47.794  Millions
Intercept Pharmaceuticals inc   5.09 $ 712.371  Millions$ 139.974  Millions
Larimar Therapeutics Inc   5.02 $ 82.006  Millions$ 16.339  Millions
Mersana Therapeutics inc   5.00 $ 112.002  Millions$ 22.384  Millions
Quoin Pharmaceuticals Ltd   4.98 $ 5.239  Millions$ 1.052  Millions
Sarepta Therapeutics Inc   4.93 $ 1,048.892  Millions$ 212.553  Millions
Bioxcel Therapeutics Inc   4.91 $ 40.252  Millions$ 8.206  Millions
Panbela Therapeutics Inc   4.90 $ 3.377  Millions$ 0.689  Millions
Agios Pharmaceuticals Inc   4.89 $ 451.897  Millions$ 92.432  Millions
Alnylam Pharmaceuticals Inc   4.88 $ 1,721.058  Millions$ 352.864  Millions
Lisata Therapeutics Inc   4.88 $ 29.161  Millions$ 5.979  Millions
Tff Pharmaceuticals Inc  4.82 $ 10.551  Millions$ 2.188  Millions
Syros Pharmaceuticals Inc   4.82 $ 108.776  Millions$ 22.570  Millions
Inovio Pharmaceuticals Inc   4.80 $ 93.799  Millions$ 19.547  Millions

Date modified: 2026-09-08T15:09:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.